Michael Jay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael Jay has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Matthew P. Sadgrove
UNC Eshelman School of Pharmacy, Division of Molecular Pharmaceutics, University of North Carolina at Chapel Hill, 125 Mason Farm Road, CB #7362, Chapel Hill, NC, 27599-7362, USA
10 shared publicationsKatsuhiko Sueda
University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Molecular Pharmaceutics, Chapel Hill, North Carolina
6 shared publicationsRussell J. Mumper
UNC Eshelman School of Pharmacy, Division of Molecular Pharmaceutics, University of North Carolina at Chapel Hill, 125 Mason Farm Road, CB #7362, Chapel Hill, NC, 27599-7362, USA
6 shared publicationsYong Zhang
Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill Chapel Hill, NCUSA
5 shared publicationsJames E. Huckle
UNC Eshelman School of Pharmacy, Division of Molecular Pharmaceutics, University of North Carolina at Chapel Hill, 125 Mason Farm Road, CB #7362, Chapel Hill, NC, 27599-7362, USA
4 shared publications- John P. Prybylski
Pharmacometrics and Systems Pharmacology, Pfizer, Groton, USA
4 shared publications
Latest Publications
- 1 January 2019
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 55, 140-144
Impact of chelation timing on gadolinium deposition in rats after contrast administration
- 1 January 2019
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 55, 140-144
Impact of chelation timing on gadolinium deposition in rats after contrast administration
- 17 December 2018
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (1) , 8
Solid-State Characterization of Three Polymorphs of an Orally Available Analog of Diethylenetriaminepentaacetic Acid
The present work investigated the physical and thermal characteristics of three polymorphic forms (namely, PF1, PF2, and PF3) of a diethyl ester analog of diethylenetriaminepentaacetic acid (C2E2)...
- 17 December 2018
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (1) , 8
Solid-State Characterization of Three Polymorphs of an Orally Available Analog of Diethylenetriaminepentaacetic Acid
The present work investigated the physical and thermal characteristics of three polymorphic forms (namely, PF1, PF2, and PF3) of a diethyl ester analog of diethylenetriaminepentaacetic acid (C2E2)...
- 1 September 2017
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 52, 42-48
Neutron-activatable radionuclide cancer therapy using graphene oxide nanoplatelets
- 1 September 2017
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 52, 42-48
Neutron-activatable radionuclide cancer therapy using graphene oxide nanoplatelets
- 14 August 2017
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 105 (12) , 3273-3280
Neutron‐activatable needles for radionuclide therapy of solid tumors
Various approaches have been undertaken to enhance the delivery of therapeutic agents, including tissue‐killing radionuclides, into solid tumors. Here, we describe the preparation of conical needles composed of Ti and Mo coated by pulsed laser deposition or chemical vapor deposition with elements (Ho and Re) that can readily yield radioactive isotopes following irradiation in a neutron flux. The radioactive needles, whose design were based on solid microneedle arrays used in transdermal drug delivery, can be produced with minimal handling of radioactivity and subsequently inserted into tumors as a means of internal radiation therapy. Ho and Re were specifically chosen because of their large neutron capture cross‐sections as well as the desirable radiotherapeutic properties of the resultant radionuclides. Neutron‐absorbing shields were also developed to prevent the production of unwanted radionuclides after neutron irradiation of the needle base materials. Neutron activation calculations showed that therapeutically significant amounts of radionuclides can be produced for treating solid tumors. Stability studies demonstrated that Re did not leach off the Mo needles. These coated neutron‐activatable needles offer a new approach to internal radiation therapy of tumors that allows precise tailoring of the absorbed radiation dose delivered to the tumor by controlling the coating thickness and the irradiation time. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 3273–3280, 2017.
- 14 August 2017
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 105 (12) , 3273-3280
Neutron‐activatable needles for radionuclide therapy of solid tumors
Various approaches have been undertaken to enhance the delivery of therapeutic agents, including tissue‐killing radionuclides, into solid tumors. Here, we describe the preparation of conical needles composed of Ti and Mo coated by pulsed laser deposition or chemical vapor deposition with elements (Ho and Re) that can readily yield radioactive isotopes following irradiation in a neutron flux. The radioactive needles, whose design were based on solid microneedle arrays used in transdermal drug delivery, can be produced with minimal handling of radioactivity and subsequently inserted into tumors as a means of internal radiation therapy. Ho and Re were specifically chosen because of their large neutron capture cross‐sections as well as the desirable radiotherapeutic properties of the resultant radionuclides. Neutron‐absorbing shields were also developed to prevent the production of unwanted radionuclides after neutron irradiation of the needle base materials. Neutron activation calculations showed that therapeutically significant amounts of radionuclides can be produced for treating solid tumors. Stability studies demonstrated that Re did not leach off the Mo needles. These coated neutron‐activatable needles offer a new approach to internal radiation therapy of tumors that allows precise tailoring of the absorbed radiation dose delivered to the tumor by controlling the coating thickness and the irradiation time. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 3273–3280, 2017.
- 1 May 2017
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 38, 145-151
The stability of gadolinium-based contrast agents in human serum: A reanalysis of literature data and association with clinical outcomes
- 1 May 2017
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 38, 145-151
The stability of gadolinium-based contrast agents in human serum: A reanalysis of literature data and association with clinical outcomes
- 1 December 2016
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 34 (10) , 1366-1372
Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood–brain barrier
- 1 December 2016
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 34 (10) , 1366-1372
Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood–brain barrier
- 1 December 2016
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 34 (10) , 1391-1393
Can gadolinium be re-chelated in vivo? Considerations from decorporation therapy
- 1 December 2016
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 34 (10) , 1391-1393
Can gadolinium be re-chelated in vivo? Considerations from decorporation therapy
- 22 April 2016
- Published by Springer Nature in The AAPS Journal
- Vol. 18 (4) , 972-980
Synthesis and Physicochemical Characterization of a Diethyl Ester Prodrug of DTPA and Its Investigation as an Oral Decorporation Agent in Rats
The increasing threats of nuclear terrorism have made the development of medical countermeasures a priority for international security. Injectable formulations of diethylenetriaminepentaacetic acid (DTPA) have been approved by the FDA; however, an oral formulation is more amenable in a mass casualty situation. Here, the diethyl ester of DTPA, named C2E2, is investigated for potential as an oral treatment for internal radionuclide contamination. C2E2 was synthesized and characterized using NMR, MS, and elemental analysis. The physiochemical properties of solubility, lipophilicity, and stability were investigated in order to predict its oral bioavailability. Finally, an animal efficacy study was conducted in Sprague Dawley rats pre-contaminated by intramuscular injection with (241)Am(NO3)3 to establish effectiveness of the therapy via the oral route. Synthesis of C2E2 yielded a crystalline powder with high solubility and improved lipophilicity over DTPA. The ester was stable in both simulated gastric and intestinal fluids over the anticipated time course of absorption. Capsules containing C2E2 were demonstrated to be stable for 12 months under accelerated stability conditions. After a single dose, C2E2 enhanced the elimination of (241)Am in a dose-dependent manner. Significant improvement was seen in both total (241)Am decorporation and reduction of (241)Am liver and skeletal burden. C2E2 was concluded to be effective when orally administered to (241)Am-contaminated rats. It may therefore have potential for medical countermeasure in treating humans contaminated with (241)Am or other transuranic elements. An oral capsule or powder for reconstitution may be suitable formulations for future development based on the physiochemical properties and anticipated dose required for efficacy.
- 22 April 2016
- Published by Springer Nature in The AAPS Journal
- Vol. 18 (4) , 972-980
Synthesis and Physicochemical Characterization of a Diethyl Ester Prodrug of DTPA and Its Investigation as an Oral Decorporation Agent in Rats
The increasing threats of nuclear terrorism have made the development of medical countermeasures a priority for international security. Injectable formulations of diethylenetriaminepentaacetic acid (DTPA) have been approved by the FDA; however, an oral formulation is more amenable in a mass casualty situation. Here, the diethyl ester of DTPA, named C2E2, is investigated for potential as an oral treatment for internal radionuclide contamination. C2E2 was synthesized and characterized using NMR, MS, and elemental analysis. The physiochemical properties of solubility, lipophilicity, and stability were investigated in order to predict its oral bioavailability. Finally, an animal efficacy study was conducted in Sprague Dawley rats pre-contaminated by intramuscular injection with (241)Am(NO3)3 to establish effectiveness of the therapy via the oral route. Synthesis of C2E2 yielded a crystalline powder with high solubility and improved lipophilicity over DTPA. The ester was stable in both simulated gastric and intestinal fluids over the anticipated time course of absorption. Capsules containing C2E2 were demonstrated to be stable for 12 months under accelerated stability conditions. After a single dose, C2E2 enhanced the elimination of (241)Am in a dose-dependent manner. Significant improvement was seen in both total (241)Am decorporation and reduction of (241)Am liver and skeletal burden. C2E2 was concluded to be effective when orally administered to (241)Am-contaminated rats. It may therefore have potential for medical countermeasure in treating humans contaminated with (241)Am or other transuranic elements. An oral capsule or powder for reconstitution may be suitable formulations for future development based on the physiochemical properties and anticipated dose required for efficacy.